HC Wainwright Has Positive Outlook for CORT FY2026 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at HC Wainwright raised their FY2026 earnings estimates for Corcept Therapeutics in a research note issued to investors on Monday, March 31st. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will earn $3.99 per share for the year, up from their previous estimate of $3.80. HC Wainwright has a “Buy” rating and a $150.00 price objective on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ FY2027 earnings at $7.46 EPS, FY2028 earnings at $9.29 EPS and FY2029 earnings at $11.10 EPS.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.11). The firm had revenue of $181.89 million during the quarter, compared to the consensus estimate of $200.12 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%.

Several other equities analysts have also issued reports on CORT. Truist Financial boosted their price objective on Corcept Therapeutics from $76.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, March 31st. Piper Sandler upped their price target on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the company an “overweight” rating in a report on Thursday. Canaccord Genuity Group raised their price objective on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, StockNews.com cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $143.25.

Corcept Therapeutics Stock Down 6.2 %

Shares of Corcept Therapeutics stock opened at $74.45 on Thursday. The company has a market capitalization of $7.85 billion, a P/E ratio of 59.09 and a beta of 0.14. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The business has a 50-day moving average of $64.81 and a two-hundred day moving average of $56.28. Corcept Therapeutics has a 1 year low of $20.84 and a 1 year high of $117.33.

Institutional Investors Weigh In On Corcept Therapeutics

Large investors have recently made changes to their positions in the stock. Synergy Asset Management LLC increased its holdings in Corcept Therapeutics by 131.3% during the fourth quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock worth $22,369,000 after buying an additional 262,503 shares during the last quarter. Van ECK Associates Corp bought a new position in shares of Corcept Therapeutics in the 4th quarter valued at about $4,483,000. State Street Corp increased its stake in shares of Corcept Therapeutics by 0.6% during the 3rd quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company’s stock worth $162,871,000 after purchasing an additional 19,893 shares during the last quarter. Burney Co. increased its stake in shares of Corcept Therapeutics by 9.1% during the 4th quarter. Burney Co. now owns 473,821 shares of the biotechnology company’s stock worth $23,876,000 after purchasing an additional 39,657 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Corcept Therapeutics by 43.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 253,070 shares of the biotechnology company’s stock valued at $11,712,000 after purchasing an additional 76,573 shares during the period. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Transactions at Corcept Therapeutics

In related news, insider Joseph Douglas Lyon sold 421 shares of the company’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $60.58, for a total transaction of $25,504.18. Following the sale, the insider now owns 9,009 shares in the company, valued at approximately $545,765.22. This represents a 4.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $50.54, for a total value of $111,188.00. The disclosure for this sale can be found here. Insiders sold 163,124 shares of company stock valued at $15,074,318 in the last ninety days. 20.50% of the stock is currently owned by corporate insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.